Non-motor symptoms in essential tremor, akinetic rigid and tremor-dominant subtypes of Parkinson’s disease

Ali S. Shalash, Eman Hamid, Hanan Elrassas, Eshak I. Bahbah, Alia H. Mansour, Hadeer Mohamed, Mahmoud Elbalkimy

1 Faculty of Medicine, Department of Neurology, Ain Shams University, Cairo, Egypt, 2 Okasha Institute of Psychiatry, Ain Shams University, Cairo, Egypt, 3 Faculty of Medicine, Al-Azhar University, Damietta, Egypt

Abstract

Objectives
To compare non-motor symptoms (NMSs) among patients with essential tremor (ET), Parkinson’s disease (PD) subtypes (akinetic-rigid type (ART) and tremor-dominant type (TDT)), and healthy controls.

Patients and methods
This retrospective study included 129 participants, 72 PD (33 PD-ART, 33 PD-TDT, and 6 Mixed), 29 ET patients, and 28 controls. PD patients were assessed by the unified Parkinson’s disease rating scale (UPDRS), Hoehn, and Yahr scale (H&Y), while ET patients were evaluated by the Fahn Tolosa Marin Tremor Rating Scale. All subjects were evaluated by non-motor symptoms scale (NMSS) for NMSs and Beck depression inventory (BDI) for depression.

Results
PD subtypes groups, ET, and controls were age and gender-matched. Compared to controls, all PD, PD subtypes, and ET showed significantly worse most of NMSs (p<0.001) and depression. Compared to ET, all PD and PD-ART had significantly worse gastrointestinal (p = 0.002), urinary symptoms (p = 0.001, p = 0.003) and depression (p = 0.002) and PD-TDT worse depression, while ET patients showed worse memory/attention than PD subtypes. Total NMSS of ET is highly correlated to depression and moderately to tremor severity and age of onset, while total of NMSS is highly correlated to depression, disease severity, and disability.

Conclusion
The current study demonstrated several comparable domains of NMSs of PD subtypes and ET, except worse gastrointestinal and urinary symptoms among PD-ART. Identifying
different NMSs profiles is important for predicting, better assessing, and tailoring management of ET and PD subtypes.

Introduction

Essential tremor (ET) and Parkinson’s disease (PD) are common tremor disorders in adults with increased prevalence with age. ET and PD affect about 4.6% [1] and 1% of populations older than 65 years [2] respectively and share overlapping clinical motor features, resulting in occasional difficulty to differentiate between them [3]. Both diseases were described mainly as motor disorders with different phenotypes, followed by recognition of associated nonmotor symptoms (NMSs). Currently, NMSs are considered an integral part in both disorders that significantly impact patients’ quality of life, demonstrating the importance of their assessment in patients’s management [3–5].

The postural and kinetic tremors of the upper limbs are the main symptoms of ET. However, other motor symptoms were reported, including gait ataxia, postural instability, disturbances of the eye movement, resting tremor, rigidity, and mild bradykinesia. Several NMSs are progressively being recognized with ET, including cognitive decline, depression, anxiety, pain, hearing impairment, and sleep problems [5,6].

Owing to the heterogeneous nature of PD, it can be classified into different subtypes; patients with predominant akinesia/rigidity that is an akinetic-rigid type (ART) and patients with a tremor-dominant type (TDT) [7]. In addition to motor differences, both subtypes showed variability of NMSs that might imply different pathophysologies. For example, PD-ART is associated with greater cognitive impairment and more rapid progression than those with TDT-PD [8]. However, few previous studies reported inconsistent differences of associated NMSs between PD subtypes; therefore, further studies are warranted. On the other hand, the link between PD and ET has been suggested by previous clinical, imaging, and pathological studies [3,9]. Nevertheless, several issues of the ET-PD relationship are still controversial [9,10]. Investigating the differences and similarities of multiple aspects, including NMSs, between both disorders might help in clinical differentiation and understanding the relationship and underlying mechanisms of both disorders.

Previous studies of variable methodology and population compared NMSs among patients with PD, PD-TDT, and ET demonstrating a remarkable overlap [9]. However, the exact difference between PD and ET in terms of NMSs profile is still debatable. Kwon et al. [11], and Lage-man et al. [12] reported that patients with PD had more NMSs compared to those with ET. On the contrary, Giorelli et al. [13] demonstrated a non-significant difference between patients with PD and ET in the total number of NMSs. Moreover, investigating NMSs profiles that distinguish between ET, PD-TDT, and PD-ART were not fully addressed. Hence, we aimed to explore differences of depression and NMSs between ET and PD phenotypes (PD-TDT and PD-ART) and their correlates.

Methods

Patients and study design

This retrospective study included 129 Egyptian adults from both genders; 72 patients with PD, 29 patients with a diagnosis of ET, and 28 healthy controls. Patients were recruited from the outpatient clinic at Ain Shams University Hospitals (Cairo, Egypt). Excluded subjects were patients with ET plus, atypical or acquired parkinsonism, patients with acquired, physiological,
dystonic, or other types of tremor, and patients with a comorbid chronic illness that might affect NMSs. The matched controls were recruited from healthy volunteers, and persons accompanied patients with other diagnoses and were evaluated to exclude ET, PD, or the presence of a family history of tremor. All subjects were non-alcoholics according to cultural norms. All subjects were comprehensively evaluated as a part of previous studies and data registry of Movement disorders outpatient clinic. The Ethical Committee at the Faculty of Medicine, Ain Shams University, approved the study that is consistent with the ethical standards of the Declaration of Helsinki. Informed written consent was provided from all subjects.

**PD criteria**

Patients with PD were diagnosed according to the British Parkinson’s disease Society Brain Bank criteria [14] and assessed by the unified Parkinson’s disease rating scale (UPDRS) and its subscores, Hoehn and Yahr scale (H&Y) for disease staging, and Schwab and England scale (S&E) for daily functioning, in medication “Off” and “On” states. Patients with PD were classified into tremor dominant type (PD-TDT) and akinetic rigid type (PD-ART), according to the ratio of the tremor score (sum of UPDRS Part III items 20 and 21, divided by 4) to the akinetic-rigid score (sum of UPDRS Part III items 22–27 and 31, divided by 15). A ratio $\geq 1$ implies a tremor-dominant type (TDT); a ratio of $\leq 0.80$ implies akinetic-rigid type (ART), while a ratio between 0.80 and 1.0 indicates a mixed type [7].

**ET criteria**

Patients with ET were diagnosed according to International Parkinsonism and Movement Disorder Society (MDS) diagnostic criteria [15] and evaluated using the Fahn Tolosa Marin Tremor Rating Scale (FTMRS) for tremor severity [16].

**Non-motor symptoms**

All subjects were evaluated using comprehensive history and neurological examination, Beck depression inventory (BDI) for depression [17], and non-motor symptoms scale (NMSS) for evaluating NMSs [18]. We used the available Arabic-validated version of BDI [19]. NMSS, is a 30 items questionnaire and composed of nine domains; cardiovascular (CVS), sleep/fatigue, mood/cognition, perceptual problems/hallucination, memory/attention, gastrointestinal tract (GIT), urinary, sexual, and miscellaneous symptoms. The frequency and severity of each NMS item were calculated, and the summary index for each domain was estimated (the sum of included items divided by the maximum possible score then multiplied by 100) to allow crude comparisons between the severity of different domains. the scale (English version) was demonstrated by expert through patients’ interview.

**Statistical analysis**

The collected data were coded and analyzed using the Statistical Package for Social Science (SPSS version 22). Categorical data were presented as frequency and percentage and compared using the Chi-Square test, while continuous data were presented as mean and standard deviation ($\pm$ SD) and compared using one-way ANOVA, accompanied by Tukey’s post hoc test. Multiple analyses were corrected with the Bonferroni method. Multiple linear regression analysis was performed. A p-value <0.05 was considered statistically significant. We performed two models; 1) unadjusted model and 2) adjusted model to age and BDI.
Results

Clinical and demographic characteristics of the study population

Seventy-two patients with PD (33 PD-ART, 33 PD-TDT, and 6 Mixed), 29 patients with ET, and 28 control individuals from both genders were enrolled in this retrospective study. The mean ages of patients with PD (all patients), ET, and controls were 53.02 ± 10.05 years, 46.14 ± 17.66 years, and 45.05 ± 16.71 years, respectively. The mean age of all patients with PD was comparable to those with ET (p = 0.60) and significantly higher than the mean age control group (p = 0.026). No significant difference between the study groups in terms of gender.

Expectedly, the duration of the disease of ET patients (10.69 ± 7.83 years) was significantly longer than patients with PD (5.01 ± 3.87 years) and PD subtypes (p < 0.001). No participants reported taking medications such as antidepressants that might affect NMSs, with only four patients were receiving propranolol to ameliorate tremor.

Mean ages of PD-TDT and ART subtypes were matched for ET (p = 0.207 and 0.457, respectively) and control groups (p = 0.113 and 0.291, respectively). Furthermore, the mean ages of ET and control groups were matched (p = 0.998). There was no significant difference between both groups PD-TDT and PD-ART, in terms of age, gender, age of onset, duration of disease, and motor functions (Table 1).

Comparison of non-motor symptoms of whole PD and ET groups

Table 2 shows the NMSs characteristics of different study groups. Patients with PD and ET had significant worse total NMSS (p<0.001), sleep/fatigue (p<0.001 and 0.002, respectively), mood/cognition (p<0.001 and 0.001, respectively), sexual (p = 0.047 and 0.011, respectively),

Table 1. Demographic and clinical characteristics of the study population.

|                        | Total PD Mean (SD) | PD-TDT Mean (SD) | PD-ART Mean (SD) | ET Mean (SD) | Control Mean (SD) |
|------------------------|--------------------|------------------|------------------|--------------|------------------|
| Number                 | 72                 | 33               | 33               | 29           | 28               |
| Gender                 |                    |                  |                  |              |                  |
| Male, n (%)            | 38 (52.7%)         | 17 (51.5%)       | 18 (54.5%)       | 21 (72.4%)   | 15 (53.6%)       |
| Female, n (%)          | 34 (47.3%)         | 16 (48.5%)       | 15 (45.5%)       | 8 (27.6%)    | 13 (46.4%)       |
| Age (years)            | 53.02 (10.05)      | 53.63 (8.81)     | 51.96 (11.29)    | 46.14 (17.66)| 45.05 (16.71)    |
| Duration of illness (years) | 5.01 (3.87)   | 5.5 (3.39)      | 4.43 (4.26)      | 10.69 (7.83) |                  |
| Age of onset (years)   | 48.02 (10.95)      | 48.19 (9.65)     | 47.5 (12.24)     | 35.37 (16.47)|                  |
| FTMRS                  | 42.51 (13.84)      |                  |                  |              |                  |
| H&Y Off                | 2.77 (1.05)        | 2.60 (0.95)      | 2.91 (1.20)      | -            | -                |
| H&Y On                 | 1.09 (0.83)        | 1.03 (0.82)      | 1.21 (0.88)      | -            | -                |
| S&E Off                | 54.92 (21.96)      | 59.68 (21.62)    | 50.30 (23.24)    | -            | -                |
| S&E On                 | 85.35 (14.32)      | 86.25 (12.88)    | 83.33 (16.32)    | -            | -                |
| UPDRS I                | 3.92 (2.60)        | 3.75 (2.51)      | 4.12 (2.87)      | -            | -                |
| UPDRS II Off           | 18.44 (10.46)      | 17.93 (10.51)    | 18.21 (10.52)    | -            | -                |
| UPDRS II on            | 6.10 (6.47)        | 5.45 (5.55)      | 6.09 (7.29)      | -            | -                |
| UPDRS III Off          | 38.57 (19.31)      | 40.24 (21.02)    | 37.03 (18.55)    | -            | -                |
| UPDRS III on           | 14.68 (12.73)      | 14.54 (13.11)    | 14.87 (13)       | -            | -                |

PD, Parkinson’s Disease; ET, essential tremor; SD, standard deviation; FTMRS, Fahn–Tolosa–Martin Tremor Rating Scale; H&Y, Hoehn and Yahr Scale; S&E, Schwab and England Scale, UPDRS, Unified Parkinson’s Disease Rating Scale; TDT, tremor dominant type; ART, akinetic rigid type.

*P<0.05 compared to control.
†P<0.05 compared to ET group.
P-value was adjusted using Bonferroni method.

https://doi.org/10.1371/journal.pone.0245918.t001
and miscellaneous NMSs (p = 0.002 and <0.001, respectively), but not perceptual problems/ hallucinations domain (p = 0.154 and 0.222, respectively). However, Bonferroni correction showed that there was no significant difference between patients with PD and controls in terms of sexual symptoms (p = 0.054). Patients with PD, not ET, showed worse GIT and urinary symptoms compared to controls (p <0.001). Patients with ET, not PD, showed worse cerebrovascular symptoms (p = 0.005) and memory/ attention (p = 0.003), compared to controls. Compared to ET, patients with PD had significantly worse GIT (p = 0.002) and urinary symptoms (p = 0.001), while comparable severity of other domains (Fig 1).

Using BDI, 84.7% of patients with PD had depression (mild, 44.3%; moderate, 29.2%; and severe,11.1%), while 69% of ET patients had depression (mild, 51.7%; moderate, 10.3%; and severe, 6.9%). Moreover, 28.6% of controls had depression (mild, 25%, and moderate, 3.6%). Patients with PD and ET patients had significantly worse BDI scores compared to controls (p<0.001 and 0.034, respectively), with worse scores among patients with PD than ET (p = 0.002). On the other hand, Bonferroni correction showed that BDI was comparable in both ET and control groups (p = 0.129).

Frequency of all NMS domains, except urinary symptoms was significantly more among ET patients compared to controls. PD patients showed more frequently impaired perception, GIT, urinary, sexual, and miscellaneous domains and depression, compared to controls. Compared to ET, PD patients showed significantly more frequently impaired GIT, urinary, and depression, and less frequently impaired memory, sexual and miscellaneous domains (Table 3). After the application of Bonferroni method, the difference between PD and ET was detected only in terms of urinary symptoms (p<0.001). Moreover, ET had higher frequency of sexual and miscellaneous symptoms compared to control group (p<0.001).

**Comparison of non-motor symptoms of PD subtypes and ET groups**

Compared to controls, PD-TDT and PD-ART groups had significant worse total NMS (p<0.001), mood/cognition (p = 0.001), GIT (p = 0.003 and <0.001, respectively), and urinary (p = 0.026 and <0.001, respectively). Miscellaneous NMS and sleep/fatigue symptoms were
significantly worse in PD-ART, not PD-TDT, compared to controls (p = 0.016 and p < 0.001, respectively).

Compared to ET, PD-TDT and PD-ART groups had comparable NMSs scores, except significantly worse GIT and urinary symptoms (p = 0.003 and 0.001, respectively) among PD-ART. Both PD-TDT and ART subtypes showed worse depression than the ET group (p = 0.018 and 0.009, respectively) and controls (p < 0.001) (Fig 1).

Compared to ET, PD-ART and PD-TDT showed significantly more frequently impaired GIT, (p = 0.048 and 0.007, respectively) urinary, (p < 0.001 and 0.001, respectively) and depression (p = 0.039 and 0.027, respectively), while less frequently impaired memory/attention (p = 0.001 and 0.007, respectively). Compared to PD-TDT, ET patients showed more frequently impaired miscellaneous domain. Compared to PD-TDT, PD-ART showed worse scores of depression, total NMSS and most of its domains, and more frequent NMSs except

![Fig 1. Means of NMSs in the study groups.](https://doi.org/10.1371/journal.pone.0245918.g001)

Table 3. Comparison of frequency of NMSs between different groups.

|                  | PD-NMSs frequency | ET-NMS frequency | Controls-NMS frequency | PD vs ET | PD vs Control | ET vs Control | ART vs Control | TDT vs ET | TDT vs TDT vs ART |
|------------------|-------------------|------------------|------------------------|---------|--------------|---------------|----------------|-----------|-------------------|
| CVS              | 66.67%            | 79.31%           | 46.43%                 | 0.208   | 0.062        | 0.01*         | 0.066          | 0.268    | 0.111             |
| Sleep            | 94.45%            | 100%             | 82.14%                 | 0.195   | 0.054        | 0.017*        | 0.053          | 0.178    | 0.345             |
| Mood             | 88.89%            | 100%             | 85.71%                 | 0.061   | 0.661        | 0.035*        | 0.282          | 0.682    | 0.178             |
| Perception       | 36.11%            | 44.82%           | 14.28%                 | 0.416   | 0.032*       | 0.012*        | 0.029*         | 0.178    | 0.665             |
| Memory/attention | 72.22%            | 100%             | 57%                    | 0.001*  | 0.721        | 0.004*        | 0.775          | 0.654    | 0.0007*           |
| GIT              | 73.62%            | 44.82%           | 14.28%                 | 0.008*  | <0.001       | 0.012*        | <0.001         | <0.001   | 0.0048*           |
| Urinary          | 76.40%            | 31.03%           | 21.43%                 | <0.001  | <0.001       | 0.41          | <0.001         | <0.001   | <0.001*           |
| Sexual           | 43.05%            | 68.97%           | 17.86%                 | 0.013*  | 0.027*       | <0.001        | 0.149          | 0.012*   | 0.007*            |
| Miscellaneous    | 79.16%            | 96.55%           | 57.14%                 | 0.027*  | 0.032*       | <0.001        | 0.02*          | 0.202    | 0.011*            |
| BDI              | 92.24%            | 68.96%           | 28.57%                 | 0.008*  | <0.001       | 0.018*        | <0.001         | <0.001   | 0.039*            |

PD, Parkinson’s Disease; ET, essential tremor; TDT, tremor dominant type; ART, akinetic rigid type.

*Non-significant after adjusting with Bonferroni correction.

https://doi.org/10.1371/journal.pone.0245918.t003
urinary and sexual domains, but without significant differences (Tables 2 and 3). Bonferroni method showed that there was no significant difference between both subtypes of PD in terms of NMSS frequency. Moreover, there was no significant difference between ET and PD-ART.

**Multivariate analysis of demographics, clinical characteristics, NMSs, and BDI in ET and PD**

In the ET group, total NMSS were significantly associated to depression (β = 2.189, p < 0.001), age of onset (β = 0.523, p = 0.032), and tremor severity (moderately) (r = 0.577, p = 0.047). Cardiovascular and memory/attention domains were significantly associated with BDI (β = 0.367, p = 0.001 and β = 0.422, p = 0.008, respectively) and disease severity (β = 0.156, p = 0.001 and β = 0.198, p = 0.004, respectively). Sleep/fatigue was associated with BDI (β = 0.471, p = 0.010), age (β = 0.170, p = 0.006), and age of onset (β = 0.170, p = 0.012). Furthermore, BDI was moderately associated with tremor severity (β = 0.166, p = 0.042) (Supplementary Table A in S1 File).

Regarding PD group, total NMSS and GIT domains were significantly associated with disease duration (β = 2.524, p = 0.045 and β = 0.409, p = 0.015, respectively), BDI (β = 2.869, p < 0.001 and β = 0.29, p = <0.001, respectively), H&Y-Off (β = 11.389, p = 0.012 and β = 1.41, p = 0.023, respectively), and S&E-Off (β = -0.745, p < 0.001 and β = -0.071, p = 0.016, respectively). Sleep/fatigue and memory domains were significantly associated with BDI (β = 0.472, p < 0.001 and β = 0.338, p = 0.001, respectively), H&Y-Off (β = 3.122, p = 0.001 and β = 1.543, p = 0.046, respectively), and S&E-Off (β = -0.200, p < 0.001 and β = -0.075, p = 0.045, respectively). Cardiovascular symptoms were associated with H&Y-Off (β = 1.023, p = 0.024, respectively) (Supplementary Table B in S1 File).

In terms of the PD-TDT subtype, total NMSs were significantly associated with BDI (β = 2.562, p < 0.001). Cardiovascular and sleep domains were significantly associated with UPDRS II-Off (β = 0.083, p = 0.047 and β = 0.285, p = 0.008, respectively). Moreover, sleep/fatigue was significantly associated with BDI and S&E-Off (β = 0.475, p < 0.001 and β = -0.136, p = 0.008, respectively) (Supplementary Table C in S1 File).

Regarding PD-ART, total NMSs was significantly associated with disease duration (β = 4.962, p = 0.006), UPDRS II-Off (β = 2.654, p = 0.015), UPDRS III-On (β = 1.227, p = 0.042), H&Y-Off (β = 17.879, p = 0.005), and S&E-Off (β = -1.213, p = 0.010). Sleep/fatigue and GIT domains were significantly associated with disease duration (β = 0.979, p = 0.003 and β = 0.753, p = 0.003, respectively), UPDRS II-Off (β = 0.357, p = 0.011 and β = 0.245, p = 0.016, respectively), BDI (β = 0.562, p = 0.001 and β = 0.485, p = 0.001, respectively), H&Y-Off (β = 3.613, p = 0.002 and β = 2.379, p = 0.008, respectively), and S&E-Off (β = -0.215, p = 0.001 and β = -0.128, p = 0.006, respectively). Mood/cognition and memory domains were associated with UPDRS II-Off (β = 0.716, p = 0.007 and β = 0.245, p = 0.016, respectively), BDI (β = 1.102, p = 0.001 and β = 0.485, p = 0.001, respectively), H&Y-Off (β = 6.256, p = 0.006 and β = 2.379, p = 0.008, respectively), and S&E-Off (β = -0.392, p = 0.001 and β = -0.128, p = 0.006, respectively) (Supplementary Table D in S1 File).

In PD group, BDI was significantly associated with disease duration of total PD (β = 0.761, p = 0.005), H&Y Off (β = 3.136, p < 0.001), UPDRS II-Off (β = 0.431, p < 0.001), and UPDRS III Off (β = 0.159, p = 0.001). In ET group, BDI was associated with disease severity (β = 0.166, p = 0.042).

**Discussion**

Several previous studies confirmed that NMSs are an integral part of ET [20,21]; however, few studies compared NMS profiles of ET and PD motor subtypes [22,23]. The current study
showed that both patients with ET and PD have worse several NMSs compared to controls and marked overlap with minimal significant differences between the two disorders. Patients with PD had significantly worse and more frequent gastrointestinal symptoms, urinary symptoms, and depression compared to ET. Compared to ET, similar differences were detected in PD-ART, while PD-TDT showed non-significant differences. To the best of our knowledge, this is the first study that compares both PD-TDT and PD-ART subtypes with ET in terms of NMSs.

Similar to current findings, Lee et al. reported a similar worse non-motor profile among patients with PD and ET compared to controls, with more frequent and worse gastrointestinal (by NMSS and SCOPA-AUT) and genitourinary symptoms (by SCOPA-AUT) among PD than ET and controls [6]. Similarly, Giorelli and his colleagues using the NMS questionnaire (NMS-Quest) showed a non-significant difference in the total number of NMSs between both ET and PD patients, with a slight increase among patients with PD [13]. However, they observed a significant increase in specific NMSs, e.g., drooling, orthostatic dizziness, and vivid dreaming in patients with PD. Different results could be explained by different assessment tools and different population characteristics, especially the older age of their groups and the low percentage of no-tremor patients (29%). Sengul et al. reported a similar frequency of most NMS-Quest items, with more frequently reported constipation, incomplete bowel emptying, and loss of taste/smell by patients with PD than ET patients [22].

Interestingly, autonomic dysfunctions, especially gastrointestinal and urinary symptoms, were more discriminative between both disorders, similar to prior studies [6,24]. Patients with PD had worse and more frequent symptoms compared to controls and ET, while ET patients were indifferent from controls. Consistently, Damian et al. reported worse autonomic scores of SCOPA-Aut of PD rather than ET patients [24]. In addition to more extensive brainstem neurodegeneration in PD, documented peripheral alpha-synuclein pathology in the spinal cord and enteric, parasympathetic nervous system in contrast to ET [24,25].

In the current study, depression was more reported and worse among patients with ET and PD than healthy controls. Moreover, patients with PD had more frequent and worse depression in relation to ET. Consistently, Lee et al. showed worse depression symptoms using the Montgomery-Asberg Depression Rating Scale in PD and ET patients, with higher scores among patients with PD [6]. Other previous studies showed similar depression scores between ET and PD patients [26–28]. Smeltere and his group demonstrated significantly more depression of both disorders than controls and more depression scores in patients with PD, but in contrast, no significant difference between PD and ET was detected [26].

Furthermore, another study by Miller et al. showed no significant difference between patients with ET, PD, and dystonia in terms of BDI, depression severity, or frequency [27]. A study by Puertas-Martín et al. compared 32 ET patients with long duration to 32 patients with PD with mild disease (stages I and II) with no significant difference [28]. These variable findings could be explained by the variability of assessment tools, the number of recruited patients, disease severity, disease duration, older age of patients, non-matched groups, and received medications. Remarkably, ET patients in the current study had worse FMTRS and long duration in relation to prior studies, which might explain the high non-motor burden. In contrast, most of our patients with PD were mild to moderate stages with a relatively shorter duration of prior studies that could affect the current findings.

On the other hand, the cardiovascular symptoms and memory/attention domains were remarkably impaired among ET patients in the current study. Similarly, Lee et al. detected the main affection of these domains in ET [6]. ET’s cognitive dysfunction was detected in the current study that is worse than controls and comparable to PD in consistent with previous studies [22,23,28]. Puertas-Martín et al. showed similar non-demented ET performance and mild
PD in global cognitive functions, with marginal more worsening of memory and verbal fluency in ET [28]. Cognitive dysfunction in ET could be attributed to dysfunction of fronto-subcortical and cerebellar thalamocortical circuits [5,28].

In agreement with previous studies, correlations of NMSs were variable between ET and PD. In contrast to PD, ET NMSs did not correlate with disease duration and minimally correlated to tremor severity. Sengul et al. reported a correlation of NMS to disease severity among PD rather than ET patients [6,22]. Similarly, Lee et al. reported significant correlations of total NMSs and gastrointestinal scores with disease severity and duration among patients with PD compared to ET. They attributed different correlations to restricted and slow pathology of ET, specificity of NMSs to PD, and PD brainstem pathology [6]. Furthermore, It was observed that higher depression scores were associated with increased motor severity in both PD and ET patients, similar to previous studies [26,27].

Remarkably, PD-TDT showed higher scores of NMSs to ET, but non-significant, dissimilar to PD-ART. Furthermore, depression was more frequent and worse among PD-TDT. Moreover, PD-TDT showed significantly more frequently impaired GIT, urinary, and depression, while less frequently impaired memory/attention and miscellaneous domains compared to ET. Similarly, Kwon et al. showed similar severity of NMS of PD-TDT and ET, while PD-TDT patients had more frequent specific NMS symptoms, including hyposmia, RBD-like symptoms, urinary frequency, and memory impairment [23].

The aforementioned similarities between PD and ET in terms of total NMSs raise the question of whether there is an association between the two diseases. Several studies reported overlapping clinical motor features such as cogwheeling, postural instability, and rest tremor [29–32], and NMSs between both diseases [6,33,34]. In addition, many pathological changes were observed in the brains of patients with ET, such as a reduction of Purkinje cells (PCs) and a high incidence of torpedoes, PC axonal swellings [35,36]. These changes were accompanied by lower climbing fiber (CF) synaptic density and a higher percentage of CFs in parallel fiber territory [37], which have also been seen in patients with PD [38]. Symanski and colleagues compared PD and ET patients in terms of PC linear density, and they concluded that there was no significant difference [39]. In agreement, Rajput et al. failed to find any significant difference in the count of PCs between two groups of patients with PD and ET [40]. We suggest that this marked overlap could be explained by shared circuit dysfunction of both extrapyramidal disorders. Nevertheless, underlying mechanisms are different, with more degeneration in PD. Therefore, we believe that this overlap does not confirm a direct link and association between PD and ET.

Several studies investigated differences of NMSs between postural instability and gait disturbance (PIGD) and TDT motor subtypes of PD, aiming to characterize specific non-motor profiles and underlying pathophysiology [41]. Most studies documented worse NMSs among PIGD subtype [42]; however, few studies compared NMSs between PD-TDT and ART subtypes such as the current study. Compared to PD-TDT, our findings showed that the matched ART group had higher total NMSs, cardiovascular, sleep, fatigue, memory, gastrointestinal, urinary, and sexual symptoms, but without significant difference. Choi et al. reported no significant differences of BDI and NMSS between ART and TDT subtypes of de novo patients with PD [42]. Similarly, another study could not detect differences in non-motor burden between PD-ART and TDT [43]. Other studies showed more impairment of some NMS among patients with ART [44,45]. Wojtala et al. described less severe cognitive deficits in PD-TDT than PD-ART [46]. Variability of findings could be attributed to patients’ different clinical characteristics (disease duration, severity, and/or stage) between studies and compared groups. The lower burden of NMS in TDT is attributed to less advanced and diffuse dopaminergic and non-dopaminergic neurodegenerative changes than non-tremor dominant
phenotypes, especially PIGD [41]. This could also explain the more burden of NMS of PD-ART compared to PD-TDT in relation to ET.

Non-tremor-dominant subtypes of PD have been demonstrated to have broader NMS features, more early autonomic features, and more cognitive disturbance in advanced stages. These characteristics are attributed to more complex and diffuse central and peripheral neurodegeneration and the involvement of diverse neurotransmitters, such as dopaminergic, serotonergic, cholinergic, and noradrenergic systems [41,47,48]. Additionally, NMSs fluctuations, especially mood swings, usually associate motor fluctuation-related to chronic dopaminergic use, which is mediated by oscillations of dopaminergic and non-dopaminergic mechanisms. Therefore, most NMSs are related to several underlying pathological and biochemical mechanisms [47,48]. Consequently, targeting different underlying mechanisms is essential for proper management of NMSs, including adjustment of dopaminergic medications and targeting other non-dopaminergic neurotransmitters.

Although the significant results of this study and the relatively large sample, there were some limitations, such as the small sample size of each group, the retrospective nature of this design introduces bias into the data collection, clinic-based study with an enrollment of patients with severe symptoms especially for ET, and the limited comprehensive assessment of cognitive functions and other NMSs. The current study’s strengths include a direct comparison of ET to ART and TDT PD subtypes, and matched demographics between ET and PD, and matched disease duration and severity between PD subtypes.

In conclusion, the current study described the disparity of non-motor profiles of ET and PD motor phenotypes and their correlates. ET patients had several nonmotor symptoms comparable to PD with more prominent differences of depression, gastrointestinal, and urinary symptoms between ET and PD-ART. Identifying these different profiles is important for predicting, better assessing, and tailoring the management of NMSs of ET and PD subtypes and implies the disparity of underlying pathophysiology and neurodegeneration.

Supporting information
S1 File.

Author Contributions
Conceptualization: Ali S. Shalash, Mahmoud Elbalkimy.
Data curation: Hadeer Mohamed.
Formal analysis: Ali S. Shalash, Eshak I. Bahbah.
Investigation: Ali S. Shalash, Eman Hamid, Hanan Elrassas, Hadeer Mohamed.
Methodology: Ali S. Shalash, Eman Hamid, Hanan Elrassas, Alia H. Mansour, Hadeer Mohamed, Mahmoud Elbalkimy.
Project administration: Ali S. Shalash, Mahmoud Elbalkimy.
Software: Hadeer Mohamed.
Supervision: Ali S. Shalash, Eman Hamid, Alia H. Mansour.
Validation: Ali S. Shalash, Eman Hamid, Hanan Elrassas, Eshak I. Bahbah, Mahmoud Elbalkimy.
Visualization: Ali S. Shalash, Eshak I. Bahbah.
Writing – original draft: Ali S. Shalash, Eman Hamid, Eshak I. Bahbah.

Writing – review & editing: Ali S. Shalash, Hanan Elrassas, Eshak I. Bahbah, Alia H. Mansour, Mahmoud Elbalkimy.

References

1. Louis E.D., Ferreira J.J., How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor., Mov. Disord. 25 (2010) 534–41. https://doi.org/10.1002/mds.22838 PMID: 20175185
2. Abbas M.M., Xu Z., Tan L.C.S., Epidemiology of Parkinson’s Disease—East Versus West, Mov. Disord. Clin. Pract. (2018). https://doi.org/10.1002/mdc3.12568 PMID: 30363342
3. Thenganatt M.A., Jankovic J., The relationship between essential tremor and Parkinson’s disease, Park. Relat. Disord. (2016). https://doi.org/10.1016/j.prkd.2015.09.032 PMID: 2652219
4. Shalash A.S., Hamid E., Elrassas H.H., Bedair A.S., Abusho uk A.I., Khamis M., et al. Elbalkimy, Non-motor symptoms as predictors of quality of life in Egyptian patients with Parkinson’s disease: A cross-sectional study using a culturally adapted 39-Item Parkinson’s disease questionnaire, Front. Neurol. 9 (2018). https://doi.org/10.3389/fneur.2018.00357 PMID: 29081969
5. Shalash A.S., Mohamed H., Mansour A.H., Elkady A., Elrassas H., Hamid E., et al, Clinical Profile of Non-Motor Symptoms in Patients with Essential Tremor: Impact on Quality of Life and Age-Related Differences, Tremor Other Hyperkinet Mov. (N. Y). 9 (2019). https://doi.org/10.7916/tohm.v0.736 PMID: 31867132
6. Lee S.M., Kim M., Lee H.M., Kwon K.Y., Koh S.B., Nonmotor symptoms in essential tremor: Comparison with Parkinson’s disease and normal control, J. Neurol. Sci. 349 (2015) 168–173. https://doi.org/10.1016/j.jns.2015.01.012 PMID: 25961399
7. Kang G.A., Bronstein J.M., Masterman D.L., Redelings M., Crum J.A., Ritb C., Clinical characteristics in early Parkinson’s disease in a central California population-based study, Mov. Disord. 20 (2005) 1133–1142. https://doi.org/10.1002/mds.20513 PMID: 15964130
8. Xu C., Zhuang P., Hallett M., Zhang Y., Li J., Li Y., Parkinson’s Disease Motor Subtypes Show Different Responses to Long-Term Subthalamic Nucleus Stimulation, Front. Hum. Neurosci. 12 (2018). https://doi.org/10.3389/fnhum.2018.00365 PMID: 30337863
9. Tarakad A., Jankovic J., Essential tremor and parkinson’s disease: Exploring the relationship, Tremor and Other Hyperkinetic Movements. (2019). https://doi.org/10.7916/D8MD0GVR PMID: 30643667
10. Alqarni M., Fasano A., The overlap between Essential tremor and Parkinson disease, Park. Relat. Disord. (2018). https://doi.org/10.1016/j.prkd.2017.07.006 PMID: 28729050
11. Kwon K.Y., Lee H.M., Lee S.M., Kang S.H., Koh S.B., Comparison of motor and non-motor features between essential tremor and tremor dominant Parkinson’s disease, J. Neurol. Sci. 361 (2016) 34–38. https://doi.org/10.1016/j.jns.2015.12.016 PMID: 26810513
12. Lageman S.K., Cash T. V., Mickens M.N., Patient-reported Needs, Non-motor Symptoms, and Quality of Life in Essential Tremor and Parkinson’s Disease, Tremor and Other Hyperkinetic Movements. (2014). https://doi.org/10.7916/D8RF5S4J PMID: 24932425
13. Giorelli M., Bagnoli J., Consiglio L., Lopane M., Bosco Zimatore G., Zizza D., Difazio P., Do non-motor symptoms in Parkinson’s disease differ from essential tremor before initial diagnosis? A clinical and scintigraphic study, Parkinsonism Relat. Disord. 20 (2014) 17–21. https://doi.org/10.1016/j.parkreldis.2013.09.004 PMID: 24030307
14. Hughes A.J., Daniel S.E., Kliford L., Lees A.J., Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases., J. Neurol. Neurosurg. Psychiatry. 55 (1992) 181–4. https://doi.org/10.1136/jnnp.55.3.181 PMID: 1564476
15. Bhatia K.P., Bain P., Bajaj N., Elble R.J., Hallett M., Louis E.D., et al, Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society, Mov. Disord. 33 (2018) 75–87. https://doi.org/10.1002/mds.27121 PMID: 29193359
16. Fahn S., Tolosa E., Coneception M. Clinical rating scale for tremor In: Jankovic J, Tolosa E, eds. Parkinson’s Disease and Movement Disorders., in: Baltimore M. (Ed.), Park. Dis. Mov. Disord., Williams and Wilkins, 1993.
17. BECK A.T., WARD C.H., MENDELSO N M., MOCK J., ERBAUGH J., An inventory for measuring depression., Arch. Gen. Psychiatry. 4 (1961) 561–71. https://doi.org/10.1001/archpsyc.1961.01710120031004 PMID: 13688369
18. Chaudhuri K.R., Martinez-Martín P., Quantitation of non-motor symptoms in Parkinson’s disease, Eur. J. Neurol. 15 (2008) 2–8. https://doi.org/10.1111/j.1468-1331.2008.02212.x PMID: 18702736
19. Abdel-Khalek A.M., Internal consistency of an Arabic adaptation of the beck depression inventory in four Arab countries, Psychol. Rep. (1998). https://doi.org/10.2466/pr0.1998.82.1.264 PMID: 9520563

20. Wu Y., Wang X., Wang C., Sun Q., Song N., Zhou Y., et al, Prevalence and clinical features of non-motor symptoms of essential tremor in Shanghai rural area, Parkinsonism Relat. Disord. 22 (2016) 15–20. https://doi.org/10.1016/j.parkreldis.2015.10.617 PMID: 26777409

21. Peng J., Wang L., Li N., Li J., Duan L., Peng R., Distinct Non-motor Features of Essential Tremor with Head Tremor Patients, Acta Neurol. Scand. (2020) ane.13242. https://doi.org/10.1111/ane.13242 PMID: 32176316

22. Sengul Y., Sengul H.S., Sural M.K., Bakim B., Forta H., A comparison between rate of nonmotor symptom development in essential tremor and Parkinson's disease, Acta Neurol. Belg. 115 (2015) 289–294. https://doi.org/10.1007/s13760-014-0408-6 PMID: 25527389

23. Kwon K.-Y., Lee H.M., Lee S.-M., Kang S.H., Koh S.-B., Comparison of motor and non-motor features between essential tremor and tremor dominant Parkinson’s disease, J. Neurol. Sci. 361 (2016) 34–38. https://doi.org/10.1016/j.jns.2015.12.016 PMID: 26777409

24. Damian A., Adler C.H., Hentz J.G., Shill H.A., Caviness J.N., Sabbagh M.N., et al, Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson’s disease, Parkinsonism Relat. Disord. 18 (2012) 1089–1093. https://doi.org/10.1016/j.parkreldis.2012.06.008 PMID: 22771283

25. Jellinger K.A., Neuropathobiology of non-motor symptoms in Parkinson disease, J. Neural Transm. 122 (2015) 1429–1440. https://doi.org/10.1007/s00702-015-1405-5 PMID: 25976432

26. Smeltere L., Kuznecovs V., Erts R., Depression and social phobia in essential tremor and Parkinson’s disease, Brain Behav. 7 (2017) e00781. https://doi.org/10.1002/brb3.781 PMID: 28948077

27. Miller K.M., Okun M.S., Fernandez H.F., Rodriguez R.L., Bowers D., Depression symptoms in movement disorders: Comparing Parkinson’s disease, dystonia, and essential tremor, Mov. Disord. 22 (2007) 666–672. https://doi.org/10.1002/mds.21376 PMID: 17266084

28. Puertas-Martín V., Villarejo-Galende A., Fernández-Guiñez S., Romero J.P., Louis E.D., Benito-León J., A Comparison Study of Cognitive and Neuropsychiatric Features of Essential Tremor and Parkinson’s Disease., Tremor Other Hyperkinet. Mov. (N. Y). 6 (2016) 431. https://doi.org/10.7916/D86H4HRN PMID: 28105386

29. Dirix M.F., Zach H., Bloem B.R., Hallett M., Helmich R.C., The nature of postural tremor in Parkinson disease, Neurology. 90 (2018) e1095–e1103. https://doi.org/10.1212/WNL.0000000000005215 PMID: 29476038

30. Cohen O., Pullman S., Jurewicz E., Watner D., Louis E.D., Rest Tremor in Patients With Essential Tremor, Arch. Neurol. 60 (2003) 405. https://doi.org/10.1001/archneur.60.3.405 PMID: 12633153

31. Lou J.-S., Jankovic J., Essential tremor: Clinical correlates in 350 patients, Neurology. 41 (1991) 234–234. https://doi.org/10.1212/wnl.41.2_part_1.234 PMID: 1992367

32. Belvisi D., Conte A., Bologna M., Bloise M.C., Suppa A., Formica A., et al, Re-emergent tremor in Parkinson’s disease, Parkinsonism Relat. Disord. 36 (2017) 41–46. https://doi.org/10.1016/j.parkreldis.2016.12.012 PMID: 28007517

33. Lacerte A., Chouinard S., Jodoin N., Bernard G., Rouleau G.A., Panisset M., Increased Prevalence of Non-motor Symptoms in Essential Tremor., Tremor Other Hyperkinet. Mov. (N. Y). 4 (2014) 162. https://doi.org/10.7916/D86H4HRN PMID: 25247108

34. Gerbin M., Viner A.S., Louis E.D., Sleep in essential tremor: A comparison with normal controls and Parkinson’s disease patients, Parkinsonism Relat. Disord. 18 (2012) 279–284. https://doi.org/10.1016/j.parkreldis.2011.11.004 PMID: 22130149

35. Louis E.D., Faust P.L., Vonsattel J.-P.G., Honig L.S., Rajput A., Rajput A., et al, Torpedoes in Parkinson’s disease, Alzheimer’s disease, essential tremor, and control brains, Mov. Disord. 24 (2009) 1600–1605. https://doi.org/10.1002/mds.22567 PMID: 19526585

36. Rajput A.H., Rajput A., Significance of cerebellar Purkinje cell loss to pathogenesis of essential tremor, Parkinsonism Relat. Disord. 17 (2011) 410–412. https://doi.org/10.1016/j.parkreldis.2011.05.008 PMID: 21636310

37. Lee D., Gan S.-R., Faust P.L., Louis E.D., Kuo S.-H., Climbing fiber-Purkinje cell synaptic pathology across essential tremor subtypes, Parkinsonism Relat. Disord. 51 (2018) 24–29. https://doi.org/10.1016/j.parkreldis.2018.02.032 PMID: 29482925

38. Kuo S.-H., Lin C.-Y., Wang J., Sims P.A., Pan M.-K., Liou J., et al, Climbing fiber-Purkinje cell synaptic pathology in tremor and cerebellar degenerative diseases, Acta Neuropathol. 133 (2017) 121–138. https://doi.org/10.1007/s00401-016-1626-1 PMID: 27704282
39. Symanski C., Shill H.A., Dugger B., Hentz J.G., Adler C.H., Jacobson S.A., et al, Essential tremor is not associated with cerebellar Purkinje cell loss, Mov. Disord. 29 (2014) 496–500. https://doi.org/10.1002/mds.25845 PMID: 24532134

40. Rajput A.H., Robinson C.A., Rajput M.L., Robinson S.L., Rajput A., Essential tremor is not dependent upon cerebellar Purkinje cell loss, Parkinsonism Relat. Disord. 18 (2012) 626–628. https://doi.org/10.1016/j.parkreldis.2012.01.013 PMID: 22306459

41. Marras C., Chaudhuri K.R., Nonmotor features of Parkinson’s disease subtypes, Mov. Disord. 31 (2016) 1095–1102. https://doi.org/10.1002/mds.26510 PMID: 26661861

42. Choi S.-M., Kim B.C., Cho B.-H., Kang K.W., Choi K.-H., Kim J.-T., et al, Comparison of two motor subtype classifications in de novo Parkinson’s disease, Parkinsonism Relat. Disord. 54 (2018) 74–78. https://doi.org/10.1016/j.parkreldis.2018.04.021 PMID: 29703644

43. Pont-Sunyer C., Hotter A., Gaig C., Seppi K., Compta Y., Katzenschlager R., et al, The Onset of Nonmotor Symptoms in Parkinson’s disease (The ONSET PDStudy), Mov. Disord. 30 (2015) 229–237. https://doi.org/10.1002/mds.26077 PMID: 25449044

44. Konno T., Deutschländer A., Heckman M.G., Ossi M., Vargas E.R., Strongosky A.J., et al, Comparison of clinical features among Parkinson’s disease subtypes: A large retrospective study in a single center, J. Neurol. Sci. 386 (2018) 39–45. https://doi.org/10.1016/j.jns.2018.01.013 PMID: 29406964

45. Khedr E.M., El Fetoh N.A., Khalifa H., Ahmed M.A., El Beh K.M.A., Prevalence of non motor features in a cohort of Parkinson’s disease patients, Clin. Neurol. Neurosurg. 115 (2013) 673–677. https://doi.org/10.1016/j.clineuro.2012.07.032 PMID: 22902078

46. Wojtala J., Heber I.A., Neuser P., Heller J., Kalbe E., Rehberg S.P., et al, Cognitive decline in Parkinson’s disease: The impact of the motor phenotype on cognition, J. Neurol. Neurosurg. Psychiatry. 90 (2019) 171–179. https://doi.org/10.1136/jnnp-2018-319008 PMID: 30297519

47. Ray Chaudhuri K., Poewe W., Brooks D., Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features, Mov. Disord. 33 (2018) 909–919. https://doi.org/10.1002/mds.27386 PMID: 30134055

48. Titova N., Padmakumar C., Lewis S.J.G., Chaudhuri K.R., Parkinson’s: a syndrome rather than a disease?, J. Neural Transm. 124 (2017) 907–914. https://doi.org/10.1007/s00702-016-1667-6 PMID: 28028643